FHIR Cross-Version Extensions package for FHIR R4B from FHIR R3
0.0.1-snapshot-2 - informative International flag

FHIR Cross-Version Extensions package for FHIR R4B from FHIR R3 - Version 0.0.1-snapshot-2. See the Directory of published versions

CodeSystem: v3 Code System substanceAdminSubstitution

Official URL: http://hl7.org/fhir/v3/substanceAdminSubstitution Version: 2016-11-11
Standards status: Informative Maturity Level: 0 Computable Name: v3 Code System substanceAdminSubstitution

Identifies what sort of change is permitted or has occurred between the therapy that was ordered and the therapy that was/will be provided.

This Code system is referenced in the content logical definition of the following value sets:

Properties

This code system defines the following properties for its concepts

NameCodeURITypeDescription
Not Selectable notSelectable http://hl7.org/fhir/concept-properties#notSelectable boolean Indicates that the code is abstract - only intended to be used as a selector for other concepts

Concepts

This case-sensitive code system http://hl7.org/fhir/v3/substanceAdminSubstitution defines the following codes in a Is-A hierarchy:

LvlCodeDisplayDefinitionNot Selectable
1 _ActSubstanceAdminSubstitutionCode ActSubstanceAdminSubstitutionCode

Description: Substitution occurred or is permitted with another product that may potentially have different ingredients, but having the same biological and therapeutic effects.

 true
2   E equivalent

Description: Substitution occurred or is permitted with another bioequivalent and therapeutically equivalent product.
3     EC equivalent composition

Description:

                    Substitution occurred or is permitted with another product that is a:

                    
                       pharmaceutical alternative containing the same active ingredient but is formulated with different salt, ester
                       pharmaceutical equivalent that has the same active ingredient, strength, dosage form and route of administration
                    
                    
                       Examples: 
                    

                    
                       
                          Pharmaceutical alternative: Erythromycin Ethylsuccinate for Erythromycin Stearate
                       
                          Pharmaceutical equivalent: Lisonpril for Zestril
4       BC brand composition

Description:

                    Substitution occurred or is permitted between equivalent Brands but not Generics

                    
                       Examples: 
                    

                    
                       Zestril  for Prinivil
                       Coumadin for Jantoven
4       G generic composition

Description: Substitution occurred or is permitted between equivalent Generics but not Brands

                       Examples: 
                    

                    
                       Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp)
3     TE therapeutic alternative

Description: Substitution occurred or is permitted with another product having the same therapeutic objective and safety profile.

                       Examples: 
                    

                    
                       ranitidine for Tagamet
4       TB therapeutic brand

Description: Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics

                       Examples: 
                    

                    
                       Zantac for Tagamet
4       TG therapeutic generic

Description: Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands

                       Examples: 
                    

                    
                       Ranitidine  for cimetidine
2   F formulary

Description: This substitution was performed or is permitted based on formulary guidelines.
2   N none

No substitution occurred or is permitted.